Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04415749 · ClinicalTrials.gov registry record · Phase 1
NasoShield in Healthy Adults to Study Safety and Immunogenicity
A Phase 1 study, sponsored by Altimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT04415749: Completed Phase 1 study, sponsored by Altimmune.
NCT04415749 is a Phase 1 study that has completed, run by Altimmune. The registered enrollment target is 43 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04415749, a Phase 1 study, has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety for up to two doses of NasoShield, to determine if antibodies that protect against anthrax are formed after treatment with NasoShield, and to determine whether the formation of these antibodies are affected by different positions of administration.
Primary Outcome
Subjects will record solicited local and systemic events for 7 days after each dose
Interventions
- OTHER Placebo
- BIOLOGICAL NasoShield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2021-03-15 |
| Phase | Phase 1 |
What the finished NCT04415749 record still lists
NCT04415749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04415749 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04415749 about?
NCT04415749 is a clinical study titled "NasoShield in Healthy Adults to Study Safety and Immunogenicity". The purpose of this study is to evaluate the safety for up to two doses of NasoShield, to determine if antibodies that protect against anthrax are formed after treatment with NasoShield, and to determine whether the formation of these antibodies are affected by different positions of administration.
What is the current status of trial NCT04415749?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2020-06-15. Estimated completion is 2021-03-15.
What interventions are being tested in trial NCT04415749?
The interventions under investigation include: Placebo (OTHER), NasoShield (BIOLOGICAL).
Who is sponsoring clinical trial NCT04415749?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04415749's enrollment target sits among peer trials
43 1100th of 2000 higher than 896 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI